- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Oncopeptides AB (ONCO)
Assess today's live Oncopeptides AB (ONCO) share price, performance and insights using our live Stockholm: ONCO stock exchange data.
Analyse the historical data and Oncopeptides AB share price performance charts on this page. Our technical summary section provides analysis on Oncopeptides share price buy/sell indicators using real-time data (or discuss the Oncopeptides (ONCO) stock price today with other investors in the Oncopeptides ST share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ST ONCO share price (ISIN: SE0009414576) to enhance your trading decisions with our free investment tools and resources.
What Is the Oncopeptides AB Share Price Today?
The Oncopeptides share price today is 1.336.
What Is the Stock Symbol for Oncopeptides AB
The stock symbol (or 'ticker') for Oncopeptides AB is "ONCO."
What Stock Exchange Does Oncopeptides AB Trade On?
Oncopeptides AB is listed and trades on the Stockholm stock exchange.
Is Oncopeptides AB a Good Stock to Buy?
Determining whether Oncopeptides AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Oncopeptides AB share price performance charts on this page. Our technical summary section provides analysis on Oncopeptides share price buy/sell indicators using real-time data (or discuss the Oncopeptides (ONCO) stock price today with other investors in the Oncopeptides ST share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current ST ONCO share price (ISIN: SE0009414576) to enhance your trading decisions with our free investment tools and resources.
What Is the Oncopeptides AB Share Price Today?
The Oncopeptides share price today is 1.336.
What Is the Stock Symbol for Oncopeptides AB
The stock symbol (or 'ticker') for Oncopeptides AB is "ONCO."
What Stock Exchange Does Oncopeptides AB Trade On?
Oncopeptides AB is listed and trades on the Stockholm stock exchange.
Is Oncopeptides AB a Good Stock to Buy?
Determining whether Oncopeptides AB—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
1.336
-0.013(-0.96%)
Closed·
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.335
1.370
52 wk Range
1.327
6.960
ONCO is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
1.3351.370
52 wk Range
1.3276.960
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ONCO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Quickly burning through cash
- Enzymatica appoints Holger Lembrér as new CFO
- Investing.com
- Enzymatica appoints Holger Lembrér as new CFO
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell
Oncopeptides AB (publ), a biotech company, engages in the research, development, and commercialization of targeted therapies for difficult-to-treat hematological diseases in the United States, Europe, and internationally. Its lead product candidate is Pepaxti (melflufen), a drug conjugate for the treatment of relapsed refractory multiple myeloma in adult patients. The company’s PDC platform designed with two components, peptide carrier and a cytotoxic payload which utilizes the altered metabolism of cancer cells to hydrolyze PDC into active hydrophilic metabolites, which lead to an enrichment in cancer cells. It offers OPD5, OPDC3, and Gliopep for the treatment of hematological or solid tumors, and glioblastoma. The company also provides Small Polypeptide based Killer Engagers (SPiKE) platform that is designed to bind to both NK-cells and specific targets on various cancer cells. Oncopeptides AB (publ) was incorporated in 2000 and is headquartered in Stockholm, Sweden.
Oncopeptides AB Earnings Call Summary for Q3/2025
- Oncopeptides reported a 174% YoY increase in Q3 2025 net sales to SEK 20.2M, despite a 12.44% stock drop in pre-market trading following the announcement.
- Gross profit reached SEK 19.9M with a 99% margin, while operating expenses decreased by 3% YoY, improving EBIT from -SEK 61.3M to -SEK 47.1M.
- The company strengthened its cash position to SEK 147.9M following a successful rights issue and expanded its European commercial presence with market access in Spain and Italy.
- CEO Sofia Heigis confirmed Oncopeptides is targeting profitability by end-2026, citing 'four consecutive quarters of growth' and 'disciplined cost management.'
- Future strategy includes expanding European market presence, exploring Japanese market entry, and continuing development of its Spike platform with NK cell engagement technology.
Last Updated: 05/11/2025, 08:50
Read Full TranscriptCompare ONCO to Peers and Sector
Metrics to compare | ONCO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipONCOPeersSector | |
|---|---|---|---|---|
P/E Ratio | −2.1x | 7.0x | −0.4x | |
PEG Ratio | −0.06 | 0.01 | 0.00 | |
Price/Book | −9.0x | 4.6x | 2.6x | |
Price / LTM Sales | 7.4x | 5.7x | 3.2x | |
Upside (Analyst Target) | 107.6% | 120.0% | 46.7% | |
Fair Value Upside | Unlock | −8.6% | 7.6% | Unlock |
Earnings
Latest Release
19/02/2026
EPS / Forecast
-0.25 / --
Revenue / Forecast
18.57M / 46M
People Also Watch
FAQ
What Is the Oncopeptides (Stockholm: ONCO) Share Price Today?
The Oncopeptides stock price today is 1.336 SEK.
What Stock Exchange Does Oncopeptides (ONCO) Trade On?
Oncopeptides is listed and trades on the Stockholm Stock Exchange.
What Is the Ticker (Stock Symbol) for Oncopeptides?
The stock symbol (also called a 'ticker') for Oncopeptides is "ONCO."
What Is the Current Oncopeptides Market Capitalisation?
As of today, Oncopeptides (Stockholm: ONCO) market cap is 534.430M SEK.
What Is Oncopeptides's (ONCO) Earnings Per Share (TTM)?
The Oncopeptides EPS is currently -1.100 (Trailing Twelve Months).
When Is the Next Oncopeptides Earnings Date?
Oncopeptides's next earnings report will be released on 13/05/2026.
Is ONCO a Buy or Sell From a Technical Analyst Perspective?
Based on today's Oncopeptides moving averages and other technical indicators, the daily buy/sell signal for ONCO stock is Strong Sell.
How Many Times Has Oncopeptides Stock Split?
Oncopeptides has split 0 times. (See the ONCO stock split history page for full effective split date and price information.)
How Many Employees Does Oncopeptides Have?
Oncopeptides has 75 employees, based on their latest Companies House report.
What is the current trading status of Oncopeptides (Stockholm: ONCO)?
As of 24/04/2026, Oncopeptides (ONCO) is trading at a share price of 1.336 SEK, with a previous close of 1.349 SEK. The stock has fluctuated within a day range of 1.335 SEK to 1.370 SEK, while its 52-week range spans from 1.327 SEK to 6.960 SEK.
What Is Oncopeptides (ONCO) Price Target According to Analysts?
The average 12-month price target for Oncopeptides is 2.800 SEK, with a high estimate of 2.8 SEK and a low estimate of 2.8 SEK. 0 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Strong Buy. The stock has an +109.58% Upside potential.
Industry Spotlight
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.